Kraig Biocraft Laboratories (KBLB) Cash & Equivalents (2010 - 2025)

Kraig Biocraft Laboratories (KBLB) has 16 years of Cash & Equivalents data on file, last reported at $1.9 million in Q4 2025.

• For the quarter ending Q4 2025, Cash & Equivalents rose 54.07% year-over-year to $1.9 million; the trailing twelve-month figure through Dec 2025 stood at $1.9 million (up 54.07% YoY), and the FY2025 full-year result was $1.9 million, up 54.07% from the prior year.
• Cash & Equivalents grew to $1.9 million in Q4 2025, from $596936.0 in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $4.8 million in Q2 2022 to a low of $397001.0 in Q1 2025.
• A 5-year average of $2.4 million and a median of $2.5 million in 2021 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents soared 6603.6% in 2021 and sank 80.61% in 2025, its largest moves.
• Tracing KBLB's Cash & Equivalents over 5 years: stood at $2.4 million in 2021, then surged by 64.02% to $3.9 million in 2022, then slipped by 24.85% to $2.9 million in 2023, then plunged by 57.46% to $1.2 million in 2024, then surged by 54.07% to $1.9 million in 2025.
• Business Quant data shows KBLB's Cash & Equivalents at $1.9 million in Q4 2025, $596936.0 in Q3 2025, and $766113.0 in Q2 2025.